The nation of Zimbabwe has declined a substantial US health deal valued at $367m (£272m) spanning five years over the United States' demand for confidential biological samples.
This move became public after a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson has since explained that the US was demanding access to biological samples for scientific study and profit while refused to guarantee the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more dialogue to secure a deal suitable to all parties so the country's vital HIV programme can continue.
Wider Background
This rejection follows a comparable case in Kenya, where a high court suspended a similar health funding agreement following concerns were filed about the security of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government agreements to enhance openness and accountability.
According to reports, 16 African countries have so far agreed to these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this partnership might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its biological resources and data indefinitely, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"Effectively, our nation would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our citizens should a new pandemic emerge."
Sovereignty and International Frameworks
He also pointed out that the American exit from the global health body and its push of bilateral health agreements were upending systems already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This mechanism is designed to guarantee that when a country contributes its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation could be designed in a manner that honours the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that talks should continue considering a large portion of the country's Aids initiatives were funded by foreign aid.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," the group said.
This impasse emphasises the ongoing debate between receiving vital international aid and protecting a country's data in an ever more interconnected world.